View in EDS

Generalizability of the Progressive Resistance Training versus Total Hip Arthroplasty (PROHIP) trial: a cross-sectional study of 402 patients in Denmark

Saved in:
Bibliographic Details
Title: Generalizability of the Progressive Resistance Training versus Total Hip Arthroplasty (PROHIP) trial: a cross-sectional study of 402 patients in Denmark
Authors: Thomas Frydendal, Robin Christensen, Inger Mechlenburg, Lone Ramer Mikkelsen, Claus Varnum, Manuel Josef Bieder, Stig Storgaard Jakobsen, Søren Overgaard, Kim Gordon Ingwersen
Source: Frydendal, T, Christensen, R, Mechlenburg, I, Mikkelsen, L R, Varnum, C, Bieder, M J, Jakobsen, S S, Overgaard, S & Ingwersen, K G 2025, ' Generalizability of the Progressive Resistance Training versus Total Hip Arthroplasty (PROHIP) trial : a cross-sectional study of 402 patients in Denmark ', Acta Orthopaedica, vol. 96, pp. 698-705 . https://doi.org/10.2340/17453674.2025.44756
Publisher Information: MJS Publishing, Medical Journals Sweden AB, 2025.
Publication Year: 2025
Subject Terms: Male, Arthroplasty, Replacement, Hip/methods, Cross-Sectional Studies, Treatment Outcome, Denmark, Osteoarthritis, Hip/surgery, Humans, Female, Patient Reported Outcome Measures, Middle Aged, Resistance Training/methods, Aged
Description: Background and purpose: There is ongoing debate over whether results from randomized trials assigning patients to surgery or first-line treatment can be generalized to clinical practice. Therefore, we aimed to compare patients with hip osteoarthritis accepting enrollment in the Progressive Resistance Training versus Total Hip Arthroplasty (PROHIP) trial in Denmark with those declining (enrolled in an observational cohort [non-PROHIP]).Methods: We used a cross-sectional study design to compare demographics and patient-reported outcomes among patients eligible for enrollment in the PROHIP trial. We used the standardized difference (StdDiff), the absolute difference with 95% confidence interval (CI), and the propensity (odds ratio [OR]) of accepting participation in the PROHIP trial to assess imbalances between groups. We pre-specified that StdDiff values < 0.2 indicated a negligible difference, whereas values ≥ 0.8 indicated incomparability.Results: 402 patients were included, with 109 in the PROHIP trial and 293 in the non-PROHIP cohort. Patients enrolled in the PROHIP trial had a mean (standard deviation [SD]) Oxford Hip Score at baseline of 25.1 (SD 5.9) compared with 22.6 (SD 6.9) in the non-PROHIP cohort (between-group difference, 2.5 points [CI 1.1–4.0], StdDiff 0.4, OR 1.06 [CI 1.02–1.10]). This pattern was consistent across almost all secondary patient-reported outcomes applied in the PROHIP trial. For most demographic variables, there were negligible between-group differences at baseline.Conclusion: We found minimal imbalances in some baseline demographic variables and most patient-reported outcomes, with those who accepted enrollment in the PROHIP trial having more favorable outcomes at recruitment than those who declined. However, most differences were not clinically important.
Document Type: Article
File Description: application/pdf
ISSN: 1745-3682
1745-3674
DOI: 10.2340/17453674.2025.44756
Access URL: https://curis.ku.dk/ws/files/513506862/17217-FRYDENDAL_D.pdf
Rights: CC BY
Accession Number: edsair.doi.dedup.....5560c143acc689e8f1d58a69c1221c07
Database: OpenAIRE
Description
Abstract:Background and purpose: There is ongoing debate over whether results from randomized trials assigning patients to surgery or first-line treatment can be generalized to clinical practice. Therefore, we aimed to compare patients with hip osteoarthritis accepting enrollment in the Progressive Resistance Training versus Total Hip Arthroplasty (PROHIP) trial in Denmark with those declining (enrolled in an observational cohort [non-PROHIP]).Methods: We used a cross-sectional study design to compare demographics and patient-reported outcomes among patients eligible for enrollment in the PROHIP trial. We used the standardized difference (StdDiff), the absolute difference with 95% confidence interval (CI), and the propensity (odds ratio [OR]) of accepting participation in the PROHIP trial to assess imbalances between groups. We pre-specified that StdDiff values < 0.2 indicated a negligible difference, whereas values ≥ 0.8 indicated incomparability.Results: 402 patients were included, with 109 in the PROHIP trial and 293 in the non-PROHIP cohort. Patients enrolled in the PROHIP trial had a mean (standard deviation [SD]) Oxford Hip Score at baseline of 25.1 (SD 5.9) compared with 22.6 (SD 6.9) in the non-PROHIP cohort (between-group difference, 2.5 points [CI 1.1–4.0], StdDiff 0.4, OR 1.06 [CI 1.02–1.10]). This pattern was consistent across almost all secondary patient-reported outcomes applied in the PROHIP trial. For most demographic variables, there were negligible between-group differences at baseline.Conclusion: We found minimal imbalances in some baseline demographic variables and most patient-reported outcomes, with those who accepted enrollment in the PROHIP trial having more favorable outcomes at recruitment than those who declined. However, most differences were not clinically important.
ISSN:17453682
17453674
DOI:10.2340/17453674.2025.44756